A PYMNTS Company

Argentina: After 5 years, CNDC revives Farmacity file

By  |  April 16, 2018

Farmacity, a company owned by cabinet member Mario Quintana, could be allowed to operate in the province of Buenos Aires, pending the opinion of Interim Attorney General Eduardo Casal and further ratification by the Supreme Court, in a case that may decide which pharmacies owned by private companies could operate in the territory of Buenos Aires.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The current law in the province allows, since 1987, the opening of pharmacies owned by single proprietors, but not by corporations such as Farmacity, as pharmacies were seen not as businesses, but rather as “a public service, an extension of the health system.” Farmacity has challenged this determination, beginning in 2012, until reaching the Supreme Court.

    Mario Quintana announced that he will sell his shares in Farmacity in order to “avoid an eventual conflict of interest” with the company’s possible arrival to the country’s most populous province. However, provincial deputy Lisandro Bonelli has accused the Attorney General of yielding to pressure from Quintana.

    With this case, the National Commission for the Defense of Competition (CNDC) opted to reopen the file that had been frozen 5 years ago on Farmacity, considering that the evidence presented by the pharmaceutical company was sufficient. For this reason, it had decided to charge the Argentine Pharmaceutical Confederation (COFA) and the Argentine Federation Pharmacy Chambers for discriminatory behaviors denounced by Farmacity.
    Full Content: La Arena

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.